28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
A 26-wk group-based exercise program combined with dual-task training improved GCF in community-dwelling older adults without dementia. 3 key findings →
Design: randomized controlled trial Participants: 44 Evidence: high
Full summary, score breakdown and related studies → Original source
Our findings suggest that older adults at higher dementia risk due to diabetes can show improvements in both cognition and disease self-management following home-based multidomain computerized cognitive training. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Dementia cases are on the rise and researchers seek innovative ways to prevent or ameliorate cognitive impairment in later life. 3 key findings →
Participants: 30 Evidence: high
Full summary, score breakdown and related studies → Original source
Present results suggest that repeated cycles of CT in patients with AD treated with ChEIs are associated with benefits in several areas of cognitive function. 3 key findings →
Design: randomized controlled trial Participants: 16 Evidence: high
Full summary, score breakdown and related studies → Original source
15 care sites with 289 residents were randomly assigned. 2 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
Multifactorial intervention was not effective in preventing falls in older people with cognitive impairment and dementia presenting to the accident and emergency department after a fall. 2 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
Treatment of acutely sick, frail, older patients in a GEMU substantially reduced mortality. 2 key findings →
Design: randomized controlled trial Participants: 127 Evidence: high
Full summary, score breakdown and related studies → Original source
Purpose of the study The purpose of this study was to test the impact of Function-Focused Care for the Cognitively Impaired Intervention on nursing home residents with dementia and the nursing assistants who care for them. 2 key findings →
Design: randomized controlled trial Participants: 103 Evidence: high
Full summary, score breakdown and related studies → Original source
Advance care planning was effective in reducing family carer uncertainty in decision-making concerning the care of their family member and improving perceptions of quality of care in nursing homes. 2 key findings →
Design: randomized controlled trial Participants: 24 Evidence: high
Full summary, score breakdown and related studies → Original source
Specialty palliative care consultation for hospitalized patients with late-stage dementia is feasible and promising to improve decision-making and some treatment outcomes. 1 key finding →
Design: randomized controlled trial Participants: 62 Evidence: high
Full summary, score breakdown and related studies → Original source
The methods we used for intervention fidelity allowed nursing home staff to implement a goals of care decision aid intervention for advanced dementia. 1 key finding →
Design: randomized controlled trial Participants: 151 Evidence: high
Full summary, score breakdown and related studies → Original source
These preliminary results suggest that donepezil may have a potentially protective effect in Alzheimer's disease. 3 key findings →
Participants: 67 Evidence: high
Full summary, score breakdown and related studies → Original source
The results indicate that lithium treatment may have beneficial effects on cognitive performance in subjects with MCI and AD dementia. 4 key findings →
Design: meta-analysis Participants: 199 Evidence: high
Full summary, score breakdown and related studies → Original source
Some observational studies raised concern that statins may cause memory impairment, leading to a US Food and Drug Administration warning. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source
Infusion of bapineuzumab 0.5 or 1.0 mg/kg every 13 weeks for up to 3 years was generally well tolerated, with a safety and tolerability profile similar to that in previous studies. 3 key findings →
Participants: 1,462 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease, prevalent in individuals aged 60 and above, constitutes most dementia cases and significantly impairs memory and cognitive functions. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Monoclonal antibody (mAb) therapies targeting amyloid-beta (Aβ) plaques have gained prominence over the past decade as potential disease-modifying treatments for Alzheimer's disease (AD), leading to major regulatory approvals and global debate. 2 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Compared to the control group of patients, patients previously exposed to exenatide had an advantage of 5.6 points (95% CI, 2.2-9.0; p = 0.002) using blinded video rating of the MDS-UPDRS part 3 motor subscale. 1 key finding →
Design: randomized controlled trial Participants: 20 Evidence: high
Full summary, score breakdown and related studies → Original source
95 patients assigned donepezil and 99 patients assigned placebo completed the study. 1 key finding →
Participants: 128 Evidence: low
Full summary, score breakdown and related studies → Original source
The present data support the notion that lithium has disease-modifying properties with potential clinical implications in the prevention of Alzheimer's disease. 2 key findings →
Participants: 24 Evidence: high
Full summary, score breakdown and related studies → Original source
To test whether antibodies against beta-amyloid are effective in slowing progression of Alzheimer's disease, we assessed cognitive functions in 30 patients who received a prime and a booster immunization of aggregated Abeta(42) over a 1 year period in a placebo-controlled, randomized trial. 2 key findings →
Design: randomized controlled trial Participants: 30 Evidence: high
Full summary, score breakdown and related studies → Original source
This is the first randomized controlled trial with supervised moderate-to-high intensity exercise in patients with mild AD. 4 key findings →
Design: randomized controlled trial Participants: 200 Evidence: high
Full summary, score breakdown and related studies → Original source
When completed in 2022, Aging and Cognitive Health Evaluation in Elders study should provide definitive evidence of the effect of hearing treatment versus education control on cognitive decline in community-dwelling older adults with mild-to-moderate hearing impairment. 3 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
This landmark NIH-funded trial (REACH II) tested a structured, multi-part support program for 642 Hispanic, White, and Black family caregivers of people with Alzheimer's or related dementias across 5 U.S. cities. 4 key findings →
Design: RCT Participants: 642 Evidence: high
Full summary, score breakdown and related studies → Original source
Tau plays a key role in Alzheimer's disease (AD) pathophysiology, and accumulating evidence suggests that lowering tau may reduce this pathology. 1 key finding →
Design: phase-1-trial Participants: 46 Evidence: early
Full summary, score breakdown and related studies → Original source Free full text
10 of the 1,875 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →